Speeches by Cooper.

“Will the hon. Gentleman give way?”

“I wholeheartedly agree with my hon. Friend. Together with my hon. Friend the Member for Halesowen (Alex Ballinger) and the right hon. Member for Chingford and Woodford Green (Sir Iain Duncan Smith), I am an officer of the APPG on gambling reform, and we have been doing significant work to gather evidence on this issue …”

“My area of Sussex is on the fast-track devolution programme. Although that brings challenges and inevitably means that we are still building parts of the plane while learning to fly, for my constituents and all Sussex residents, the devolution of power and resources has the potential to transform our area in health, ed…”

“Effective NHS management lives or dies on the ability of our integrated care boards to address population health needs. As the devolution Bill moves forward and at pace in areas such as mine in Sussex, it brings with it more opportunity for working strategically across sectors such as health and local government. What …”

“I appreciate that and I appreciate the prevalence issue. While you cannot take an accurate indicator of prevalence from reporting, again given the extensive licensing that MHRA has done over the years, is the reporting that you are seeing, taking into account the self-reporting nature of it and the private prescribing …”

“Given that GLP-1 products have not been used as weight loss tools for nearly as long as they have been used for diabetes type 2, are you concerned about an increase in side effects being reported as GLP-1s are used more frequently for weight loss?”

“Just to be clear there, you are not seeing more side effect reporting for the new use of this established medicine than you would expect? Is it within expected parameters?”

“That is very interesting. In terms of online pharmacies are you seeing a proportionate reporting to the in-person pharmacies or are you seeing lesser reporting?”

“Thanks, panel, for being here. I am going to focus on questions around side effects and NICE appraisal. I will start with Andy and the MHRA. GLP-1s as we know have a long-standing history. They have been used for more than a decade to treat type 2 diabetes so we are well aware of their profile in that regard. In terms …”

“You have data across a wide variety of medicines so you can see the parameters of what you may expect.”

“It is a pleasure to serve under your chairship, Mr Efford. I commend my hon. Friend the Member for Peterborough (Andrew Pakes) for his continued advocacy. As someone who lived down the road in Huntingdon for many years, I am delighted to hear that Peterborough lido is up and running again, which is fantastic. Lidos are…”

“Yes.”

“Okay. Does somebody have access to that data?”

“Excellent. I thank my hon. Friend, who has nicely paid tribute to them. Well done. What has been so striking about the work we are doing is the level of local energy in our community. People care deeply about these spaces, and they want to see them thriving again. We have an opportunity to do that in a way that reflect…”

“When you say you go out looking for it, what do you do?”

“Okay. That is helpful. Let’s talk about how you are getting this information. As we have talked about, there is currently large private use of GLP-1s and we have the yellow card system to monitor side effects. Is the private use of GLP-1s having any effect on the return on yellow cards or are you seeing other ways of i…”

“It would be interesting to see those figures.”

“The yellow card reporting has been around for a long time and there have been conversations about whether it is fit for purpose or they need to use something else. Your opinion is yellow card reporting is still the best way of assessing side effects coming forward or adverse impact?”

“Okay, so just to be clear, you are not seeing any difference in the side effect profile from a type 2 diabetes patient using GLP-1s to a non-type 2 diabetes person using it for weight loss? The side effect profile is reasonably similar?”

“We have heard that before.”